XML 12 R1.htm IDEA: XBRL DOCUMENT v3.19.2
Cover
 6 Months Ended
Jun. 30, 2019
Cover [Abstract]  
Document Type 8-K/A
Amendment Flag true
Amendment Description This Amendment No. 1 to the Current Report on Form 8-K amends Item 8.01 of the Current Report on Form 8-K previously filed on July 25, 2019 to confirm that Nektar Therapeutics, a Delaware corporation ("Nektar") did not receive an action letter from the FDA regarding Nektar's NDA for NKTR-181, and as previously reported, Nektar continues to work with the FDA on the review of the NDA.
Document Period End Date Jul. 23, 2019
Entity File Number 0-24006
Entity Registrant Name NEKTAR THERAPEUTICS
Entity Central Index Key 0000906709
Entity Tax Identification Number 94-3134940
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 455 Mission Bay Boulevard South
Entity Address, City or Town San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94158
City Area Code (415)
Local Phone Number 482-5300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value
Trading Symbol NKTR
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Elected Not To Use the Extended Transition Period false